Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KyDaR: Carfilzomib Combo in NDMM
NCT04065789Phase 2Completed
- Sponsor
- Tel Aviv Sourasky Medical Center
- Start
- May 2018
- Primary completion
- Aug 2021
- Modality
- Irreversible Covalent Inhibitors, Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of carfilzomib in multiple myeloma (MM), sponsored by Tel Aviv Sourasky Medical Center. Started May 2018; status: completed.
02
Drugs
carfilzomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04065789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04065789.